Core Viewpoint - Vivos Therapeutics, Inc. has made a significant acquisition of The Sleep Center of Nevada, which is expected to enhance its revenue generation and patient demand for its obstructive sleep apnea (OSA) treatments. The company is transitioning its business model to focus on direct patient relationships and sleep center alliances [1][3]. Financial Performance - For the second quarter of 2025, Vivos reported revenue of $3.8 million, a decrease from $4.1 million in the same period of 2024. For the six months ended June 30, 2025, revenue was $6.8 million compared to $7.5 million in 2024 [4]. - Gross profit for the second quarter of 2025 was $2.1 million, down from $2.7 million in the second quarter of 2024. For the six months ended June 30, 2025, gross profit was $3.6 million compared to $4.6 million in 2024 [4]. - The gross margin declined to 55% in the second quarter of 2025 from 65% in the same period of 2024, attributed to pricing discounts and the transition to a new sales model [4]. - Operating expenses increased by 52% to $7.0 million in the second quarter of 2025, compared to $4.6 million in the same period of 2024, largely due to costs associated with the acquisition and integration of SCN [4]. Strategic Initiatives - The acquisition of The Sleep Center of Nevada marks a strategic shift in Vivos' sales and marketing approach, moving from a dentist-reliant model to a more comprehensive model that includes direct patient engagement [3]. - Vivos is also developing a new sleep practice management model to partner with sleep centers that are not interested in acquisition but want to offer Vivos' OSA diagnostic and treatment options [5][6]. - The company is actively seeking additional sleep center alliances or acquisitions to scale its new model, as demand at SCN locations has exceeded current capacity [3]. Market Context - OSA affects over 1 billion people globally, with a significant portion remaining undiagnosed. This presents a substantial market opportunity for innovative treatments that address the root causes of OSA [11]. - Vivos' proprietary treatments, including the Complete Airway Repositioning and Expansion (CARE) devices, are FDA-cleared for various severity levels of OSA, positioning the company favorably in the medical device market [10].

Core Viewpoint - Vivos Therapeutics, Inc. is set to release its second quarter 2025 financial results and will conduct a conference call to discuss these results and recent developments in the company [1][2][3] Company Overview - Vivos Therapeutics, Inc. specializes in developing and commercializing treatments for sleep-related breathing disorders, particularly obstructive sleep apnea (OSA) [4] - The company’s devices are FDA-cleared for all severity levels of OSA in adults and moderate to severe OSA in children aged 6 to 17 [4] - Vivos' Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first for moderate to severe OSA in children [4] Market Context - OSA affects over 1 billion people globally, with 90% undiagnosed, linking it to serious chronic health conditions [5] - Traditional treatments like CPAP often fail to address the root causes of OSA, indicating a need for innovative solutions [5] Strategic Initiatives - Founded in 2016, Vivos aims to empower healthcare providers to better address the needs of OSA patients through innovative technology and collaborations [6] - The company promotes The Vivos Method, a proprietary, clinically effective, nonsurgical, noninvasive, and nonpharmaceutical solution for OSA [7]